Advancing the Management of Patients with Metastatic Melanoma

ACKNOWLEDGEMENT
This activity is supported by educational grants from Merck & Co., Inc., Genentech, and Bristol-Myers Squibb.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, July 22, 2014 from 11:00 AM EST - 1:00 PM EST
Enduring Material
The enduring material will be available from July 22, 2014 to January 22, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Analyze clinical data evaluating the safety and efficacy of immunotherapies in the treatment of metastatic melanoma
Describe the mechanisms of action of new and emerging immunotherapeutic therapies for metastatic melanoma
Outline the various response patterns to immunotherapy and the related challenges in assessing response
Recognize and manage immune-related adverse events associated with immunotherapies for melanoma
Outline the role of BRAF/MEK/ERK pathway signaling in melanoma, and the development of inhibitors of this pathway
Describe the state of the science with respect to the role of alternate mutations seen in melanoma, such as NRAS, KIT, GNAQ, and GNA11
Outline new research directions in the treatment of metastatic melanoma
Apply individualized treatment strategies for a variety of patients with metastatic melanoma, including a patient with BRAF inhibitor resistance
Manage treatment-related adverse events associated with targeted therapies used in the treatment of metastatic melanoma

INTENDED AUDIENCE
This activity is intended for medical oncologists, dermatologists, surgical oncologists, pathologists, general surgeons, oncology nurse practitioners/physician assistants, oncology nurses, and other clinicians involved in the diagnosis and treatment of melanoma.

ESTIMATED TIME TO COMPLETE
This activity consists of two sessions, which should each take approximately 1 hour to complete, for a total of 2 hours.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Patrick Hwu, MD Has nothing to disclose.
Sapna Patel, MD Grant/Research: Bristol Meyers Squibb, Prometheus
Speaker's Bureau: Merck & Co.
Invited Speaker: Prometheus
Michael Davies, MD, PhD Grant/Research: GlaxoSmithKline, Genentech, Merck, Oncothyreon
Consultant: Sanofi Aventis, GlaxoSmithKline
Kevin Kim, MD Grant/Research: Genentech/Roche, Novartis
Consultant: Genentech/Roche, Novartis
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, MB,BS Speaker's Bureau: Celgene
Grant/Research: GSK
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

 

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Evolving the Management of Multiple Myeloma

ACKNOWLEDGEMENT
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Bristol-Myers Squibb.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Friday, August 22, 2014 from 10:00 AM EST - 12:00 PM EST
Enduring Material
The enduring material will be available from August 22, 2014 to February 22, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Define smoldering multiple myeloma and describe the CRAB features commonly used for disease risk stratification, and its limitations
Summarize the new mSMART definition of patients with standard-risk, intermediate-risk, and high-risk multiple myeloma

INTENDED AUDIENCE
This activity is intended for hematologic oncologists, medical oncologists, pathologists, oncology nurses and pharmacists who manage patients with multiple myeloma.

ESTIMATED TIME TO COMPLETE
This activity consists of two sessions, which should each take approximately 1 hour to complete, for a total of 2 hours.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Kenneth Anderson, MD Consultant: Celgene, Onyx, Millennium, Gilead, Sanofi Aventis
Stockholder: Oncorp, Acetylon
Philip McCarthy, MD Consultant: Celgene, Janssen, Millennium, Sanofi
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, M.B., B.S Speaker's Bureau: Celgene
Grant/Research: GSK
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Evidence-Based Management of Advanced and Metastatic Breast Cancer (MBC)

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Eisai.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, October 7, 2014 from 12:00 PM EST - 1:00 PM EST
Enduring Material
The enduring material will be available from October 7, 2014 to April 7, 2015

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Apply current practice guidelines for the management of MBC
Select and initiate cytotoxic treatment options for patients with HER2-negative, hormone receptor-negative, or hormone-refractory MBC
Analyze recent clinical trial data on novel treatments and emerging therapies for the management of MBC

INTENDED AUDIENCE
Oncologists, oncology nurses and other clinicians involved in the diagnosis and treatment of breast cancer.

ESTIMATED TIME TO COMPLETE
The activity consists of one session, which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimate that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Harold J. Burstein, MD, PhD Has nothing to disclose.
Erica L. Mayer, MD, MPH Grant/Research: Pfizer, Myriad, Eisai
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Joseph Sparano, MD  
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Advances in the Management of Lymphoma and Chronic Lymphocytic Leukemia (CLL)

ACKNOWLEDGEMENT
This activity is supported by educational grants from Genentech, Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 4.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, October 22, 2014 from 10:00 AM EST - 3:00 PM EST
Enduring Material
The enduring material will be available from October 22, 2014 to April 22, 2015

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Apply patient- and disease-specific factors in the selection of first-line, maintenance and relapsed therapy for patients with DLBCL
Identify prognostic and/or risk-stratification factors, including genetic markers, that may inform treatment decisions in patients with DLBCL
Outline new data on emerging treatment options for patients with NHL and their potential role in disease management
Describe the role of targeted biologic therapies in the management of patients with NHL
Formulate initial treatment criteria and select an initial treatment regimen for a patient with CLL
Identify the second treatment regimen for patients who may be progressing on/after initial FCR treatment
Apply an individualized approach to treatment selection for patients with CLL based on their prognosis, age, performance status, and comorbidities
Discuss current and emerging therapeutic management strategies for a patient with CLL who is older and who has comorbidities

INTENDED AUDIENCE
Hematologic oncologists, medical oncologists, pathologists, pharmacists, oncology nurses and other clinicians involved in the diagnosis and management of patients with lymphoma and chronic lymphocytic leukemia (CLL) are the target audience for this planned activity.

ESTIMATED TIME TO COMPLETE
The activity consists of four sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimate that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Andrew Zelenetz, MD, PhD Consultant: Celgene, Gilead, GSK, Hospira, Janssen, Amgen
Grant/Research: Gilead, GSK, Janssen
Andre Goy, Md, MS Consultant: Celgene
Speaker's Bureau: Pharmacyclics, Celgene, Millennium: The Takeda Oncology Company
Nicole Lamanna, MD Grant/Research: Gilead, Abbvie, Infinity Pharmaceuticals, Genentech
Consultant: Gilead, Genentech
Jennifer Brown, Md, PhD Consultant: GSK, Emergent, Morphosys, Celgene, Janssen, Pharmacyclics, Gilead, ProNai, Roche/Genentech, Kite Pharma
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, M.B., B.S Speaker's Bureau: Celgene
Grant/Research: GSK
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

New Directions in the Management of Mantle Cell Lymphoma

Presented by the Albert Einstein College of Medicine of Yeshiva University in Joint Providership with PlatformQ, LLC

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, February 17, 2015 from 1:00 PM EST - 2:00 PM EST
Enduring Material
The enduring material will be available from February 17, 2015 to August 17, 2015.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Outline the histologic types and prognostic models used in the assessment of patients with MCL
Apply evidence-based approaches to the initial treatment of patients with MCL
Implement approaches to the management of patients with relapsed/refractory MCL, with attention to new/emerging therapies

INTENDED AUDIENCE
Hematologic oncologists, pathologists, pharmacists, oncology nurses and other clinicians involved in the diagnosis and management of patients with mantle cell lymphoma are the target audience for this planned activity.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Julie M. Vose, MD, MBA Research Grant Support: Bristol-Meyers Squibb, Celgene, Genentech, GlaxoSmithKline, Incyte Corporation, Janssen Biotech, Pharmacylics, Spectrum
James O. Armitage, MD Consultant: Celgene, GlaxoSmithKline, Roche, Spectrum, Ziopharm Board of Directors: Tesario Bio, Inc.
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University has no disclosures to report relevant to this activity.
Amit K. Verma, MB,BS Has nothing to disclose relative to this activity
PlatformQ Health, Inc  
Deborah Sharkey, Senior Program Manager Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877-394-1306 or at Support@OMedLive.com

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine of Yeshiva University, OMedLive, PlatformQ Health or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Personalizing the Management of Advanced Gastric Cancer

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Lilly.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education.

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The University of Nebraska Medical Center, Center for Continuing Education designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Monday, March 2, 2015 from 2:00 PM EST - 3:00 PM EST
Enduring Material
The enduring material will be available from March 2, 2015 – September 2, 2015.

ACTIVITY DESCRIPTION
Advanced gastric cancer is an aggressive disease with poor clinical outcomes, especially in advanced disease. Although surgery followed by chemoradiotherapy is the standard protocol for treating early-stage gastric cancer that is resectable, this approach is suitable for 25% of patients with gastric cancer. For patients with advanced gastric cancer, a range of chemotherapy agents and regimens have been investigated in clinical trials in the last 20 years and are commonly used in clinical practice. However, such regimens are often unsuitable for patients with poor performance status, and both geographic and ethnic variations in disease pathogenesis and biology make the application of trial results challenging for clinicians.

Until recently, progress in targeted treatments for gastric cancer has been slower than for other solid tumors, and there have been no options for second-line therapy in the advanced setting. The recent United States Food and Drug Administration approval of a biologic agent for treating advanced gastric cancer, combined with the investigation of several other novel agents that target a range of pathways implicated in gastric cancer pathogenesis heralds a new treatment era for patients with advanced gastric cancer. Accordingly, clinicians will need education about the biology of gastric cancer to support patient selection for appropriate treatment in the advanced setting.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Summarize recent scientific research into the molecular pathways involved in the pathogenesis and progression of gastric cancer
Apply new scientific data to implement treatment strategies for managing patients with advanced gastric cancer
Describe the rationale for targeted therapies in the treatment of advanced gastric cancer

INTENDED AUDIENCE
This activity is intended for medical oncologists, gastroenterologists, pathologists, oncology nurses and other clinicians involved in the diagnosis and treatment of patients with gastric cancer.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FINANCIAL DISCLOSURES

Presenters: Disclosures:
Manish A. Shah, MD To follow prior to live activity.
Chandrakanth Are, MD Has nothing to disclose.
University of Nebraska Medical Center, Center for Continuing Education  
Lois Colburn, Executive Director Has nothing to disclose
Brenda C. Ram, CMP, CHCP, Coordinator Has nothing to disclose
PlatformQ Health, Inc  
Anne Roc, PhD, Medical Director Has nothing to disclose.
Deborah Sharkey, Senior Program Manager Has nothing to disclose.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION

Accreditation Support
Accreditation Support: Please contact the University of Nebraska Medical Center, Center for Continuing Education at conted@unmc.edu or call 402-559-4152.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Forgot Password Click Here to Register